Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C; 'Casodex' Early Prostate Cancer Trialists Group. Tyrrell CJ, et al. Radiother Oncol. 2005 Jul;76(1):4-10. doi: 10.1016/j.radonc.2005.06.005. Radiother Oncol. 2005. PMID: 16145740 Clinical Trial.
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K. Tyrrell CJ, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):476-83. doi: 10.1016/j.ijrobp.2004.03.022. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380582 Clinical Trial.
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group. See WA, et al. J Urol. 2002 Aug;168(2):429-35. J Urol. 2002. PMID: 12131282 Clinical Trial.
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Iversen P, et al. Urology. 2004 May;63(5):928-33. doi: 10.1016/j.urology.2004.02.011. Urology. 2004. PMID: 15134983 Clinical Trial.
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GR. Iversen P, et al. Among authors: tyrrell cj. Urology. 1998 Mar;51(3):389-96. doi: 10.1016/s0090-4295(98)00004-1. Urology. 1998. PMID: 9510340 Clinical Trial.
59 results